NCT06517511View on ClinicalTrials.gov

Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)

PHASE2RecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

July 11, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

April 30, 2028

Conditions
Diffuse Large B Cell Lymphoma
Interventions
DRUG

Selinexor Oral Tablet [Xpovio]

Selinexor (60mg po D1, 8) is added from the second cycle of R-CHOP regimen.

DRUG

R-CHOP Protocol

Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone

Trial Locations (2)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

510060

RECRUITING

Sun yat-sen university cancer center, Guangzhou

All Listed Sponsors
collaborator

Fudan University

OTHER

lead

Sun Yat-sen University

OTHER